Skip to main content
SpringerLink
Log in
Book cover

Handbook of Oral Anticoagulation pp 35–42Cite as

Haemorrhage risks, patient perspectives, and quality-of-life issues

  • Chapter

  • 543 Accesses

Abstract

It is estimated that, in the UK, for example, 950,000 patients are currently taking warfarin (2% of the general practice population). This number is expected to rise by approximately 10% per annum, primarily because of its use in AF [1].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modeling. Health Technol Assess 2007;11:iii–iv, ix-66.

    PubMed  CAS  Google Scholar 

  2. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial haemorrhages. Am J Med 2007;120:700–5.

    Article  PubMed  Google Scholar 

  3. Connolly SJ, Pogue J, Eikelboom J, et al.; ACTIVEW Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029–37.

    Article  PubMed  CAS  Google Scholar 

  4. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005;36:1588–93.

    Article  PubMed  Google Scholar 

  5. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007;6:981–993.

    Article  PubMed  CAS  Google Scholar 

  6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67

    Article  PubMed  Google Scholar 

  7. Mant J, Hobbs FD, Fletcher K, et al.; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503.

    Article  PubMed  CAS  Google Scholar 

  8. Poli D, Antonucci E, Marcucci R, et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 2007;121:347–52.

    Article  PubMed  CAS  Google Scholar 

  9. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91–9.

    Article  PubMed  CAS  Google Scholar 

  10. Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457–60.

    Article  PubMed  CAS  Google Scholar 

  11. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006;130:1390–6.

    Article  PubMed  Google Scholar 

  12. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting haemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713–19.

    Article  PubMed  Google Scholar 

  13. Tay KH, Lane DA, Lip GY. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin? Thromb Haemost 2008;100:955–7.

    PubMed  CAS  Google Scholar 

  14. Nieuwlaat R, Capucci A, Lip GY, et al.; Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018–26.

    Article  PubMed  CAS  Google Scholar 

  15. Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008;39:7–9.

    Article  PubMed  Google Scholar 

  16. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41–6.

    Article  PubMed  CAS  Google Scholar 

  17. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 2008;39:227–30.

    Article  PubMed  Google Scholar 

  18. Choudhry NK, Anderson GM, Laupacis A, et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141–5.

    Article  PubMed  Google Scholar 

  19. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001;323:1218–22.

    Article  PubMed  CAS  Google Scholar 

  20. Lip GY, Agnelli G, Thach AA, et al. Oral anticoagulation in atrial fibrillation: A pan-European patient survey. Eur J Intern Med 2007;18:202–8.

    Article  PubMed  CAS  Google Scholar 

  21. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000;320:1380–4.

    Article  PubMed  CAS  Google Scholar 

  22. Lane D, Lip GY. Anti-thrombotic therapy for atrial fibrillation and patients’ preferences for treatment. Age Ageing 2005;34:1–3.

    Article  PubMed  Google Scholar 

  23. Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006;110:354–58.

    Article  PubMed  Google Scholar 

  24. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448.e1-19.

    Article  PubMed  Google Scholar 

  25. Hagens VE, Ranchor AV, Van Sonderen E, et al.; RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004;43:241–7.

    Article  PubMed  Google Scholar 

  26. Jenkins LS, Brodsky M, Schron E, et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:112–20.

    Article  PubMed  Google Scholar 

  27. Das AK, Willcoxson PD, Corrado OJ, West RM. The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation. Age Ageing 2007;36:95–7.

    Article  PubMed  Google Scholar 

  28. Lancaster TR, Singer DE, Sheehan MA, et al. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 1991;151:1944–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Kok Hoon Tay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deirdre A Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory Y H Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Healthcare Ltd, a part of Springer Science+Business Media

About this chapter

Cite this chapter

Tay, K.H., Lane, D.A., Lip, G.Y.H. (2010). Haemorrhage risks, patient perspectives, and quality-of-life issues. In: Handbook of Oral Anticoagulation. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-08-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-08-1_4

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-85873-452-1

  • Online ISBN: 978-1-908517-08-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation